Rene-Olivier Casasnovas

Rene-Olivier Casasnovas

UNVERIFIED PROFILE

Are you Rene-Olivier Casasnovas?   Register this Author

Register author
Rene-Olivier Casasnovas

Rene-Olivier Casasnovas

Publications by authors named "Rene-Olivier Casasnovas"

Are you Rene-Olivier Casasnovas?   Register this Author

41Publications

1687Reads

29Profile Views

Fatigue level changes with time in long-term Hodgkin and non-Hodgkin lymphoma survivors: a joint EORTC-LYSA cross-sectional study.

Health Qual Life Outcomes 2019 Jul 2;17(1):115. Epub 2019 Jul 2.

Centre de Traitement des Données du Cancéropôle Nord-Ouest, Plateforme de Recherche Clinique Ligue Contre le Cancer, Centre François Baclesse, 3 Avenue Général Harris, 14076, Caen, Cedex 5, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12955-019-1186-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6604328PMC
July 2019

Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma.

J Clin Oncol 2018 10 20;36(28):2845-2853. Epub 2018 Aug 20.

David M. Kurtz, Florian Scherer, Michael C. Jin, Joanne Soo, Alexander F.M. Craig, Mohammad Shahrokh Esfahani, Jacob J. Chabon, Henning Stehr, Chih Long Liu, Robert Tibshirani, Lauren S. Maeda, Neel K. Gupta, Michael S. Khodadoust, Ranjana H. Advani, Ronald Levy, Aaron M. Newman, Maximilian Diehn, and Ash A. Alizadeh, Stanford University, Stanford, CA; Florian Scherer, University Medical Center Freiburg, Freiburg; Ulrich Dührsen and Andreas Hüttmann, University Hospital Essen, Essen, Germany; Michel Meignan, Hôpitaux Universitaires Henri Mondor, Creteil; René-Olivier Casasnovas, Hôpital Le Bocage, Centre Hospitalier Universitaire, Dijon, France; Jason R. Westin, University of Texas MD Anderson Cancer Center, Houston, TX; Mark Roschewski and Wyndham H. Wilson, National Cancer Institute, National Institutes of Health, Bethesda, MD; Gianluca Gaidano and Davide Rossi, University of Eastern Piedmont, Novara, Italy; and Davide Rossi, Oncology Institute of Southern Switzerland and Institute of Oncology Research, Bellinzona, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2018.78.5246DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6161832PMC
October 2018

Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma.

N Engl J Med 2018 09;379(10):934-947

From Université Lille, Centre Hospitalier Universitaire (CHU), Groupe de Recherche sur les formes Injectables et les Technologies Associées, Lille (F.M.), CHU Régional de Nancy, Service d'Hématologie, Vandoeuvre lès Nancy (P.F.), Institut Paoli-Calmettes (R.B.) and Department of Pathology, Institut Paoli-Calmettes, Centre de Recherche en Cancerologie de Marseille, INSERM, Centre National de la Recherche Scientifique, Aix-Marseille Université (L.X.), Marseille, Centre Henri Becquerel, Unité 1245 and Département d'Hématologie, Université de Rouen, Rouen (H.T.), Institut d'Hématologie de Basse Normandie, Caen (C.F.), CHU Le Bocage Service d'Hématologie Clinique, Dijon (R.-O.C.), Hôpital Henri Mondor Unité Hémopathies Lymphoïdes, Créteil (C.H.), Centre Hospitalier Départemental Vendée Service d'Onco-Hématologie, La Roche sur Yon (H.M.), Institut Universitaire du Cancer de Toulouse Oncopole Service d'Hématologie, Toulouse (L.Y.), CHU Bordeaux, Service d'Hématologie, Bordeaux (K.B.), Hôpital Saint Louis Service d'Onco-Hématologie, Paris (P.B.), Gustave Roussy Cancer, Villejuif (V.R.), Centre Hospitalier Annecy Genevois Service, Annecy (N.D.), CHU de Nantes-Hôtel Dieu Service d'Hématologie Clinique, Centre de Recherche en Cancerologie et Immunologie, INSERM, Centre National de la Recherche Scientifique, Université de Nantes, Nantes (S.L.G.), Centre Hospitalier Métropole Savoie Service Hématologie, Chambery (G.M.P.), Department of Hematology, CHU Montpellier, University of Montpellier, Montpellier (G.C.), and Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, University of Lyon, Pierre-Benite (G.A.S.) - all in France; the Department of Lymphoma and Myeloma, University of Texas M.D. Anderson Cancer Center, Houston (N.H.F.); the Department of Medicine, Memorial Sloan Kettering Cancer Center, New York (M.L.P.); the Department of Medicine, Division of Medical Oncology, University of Washington, Seattle (E.N.L.); Sarah Cannon Research Institute-Tennessee Oncology, Nashville (I.W.F.); Washington University School of Medicine, Siteman Cancer Center, St. Louis (N.L.B.); the Department of Hematology, Hospital Universitario de Salamanca and Instituto de Investigación Biomédica de Salamanca, Centro de Investigación Biomédica en Red de Cáncer, Salamanca (A.M.G.-S.), and the Department of Hematology, Hospital Clinic de Barcelona, Barcelona (A.L.-G.) - both in Spain; CHU de Québec, Hôpital de l'Enfant-Jésus, Quebec (J.-F.L.), and British Columbia Cancer Centre for Lymphoid Cancer, University of British Columbia, Vancouver (L.H.S.) - both in Canada; the Department of Hematology and Oncology, Tokai University Hospital, Kanagawa, Japan (K.A.); Instituto Português de Oncologia Lisboa Francisco Gentil Departamento de Hematologia, Lisbon (M.G.S.); the Department of Hematology, CHU Université Catholique de Louvain Namur, Yvoir (M.A.), and the Department of Hematology, Ziekenhuis Netwerk Antwerpen Stuivenberg, Antwerp (P.Z.) - both in Belgium; the Department of Hematology, National Cancer Center Hospital, Tokyo, Japan (K.T.); and Celgene, Summit, NJ (D.L., J.W.).

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/10.1056/NEJMoa1805104
Publisher Site
http://dx.doi.org/10.1056/NEJMoa1805104DOI Listing
September 2018

Antibody-Drug Conjugates for the Treatment of Hematological Malignancies: A Comprehensive Review.

Target Oncol 2018 06;13(3):287-308

Hématologie Clinique, Hôpital Le Bocage-CHU Dijon, 14 rue Paul Gaffarel, 21079, Dijon Cedex, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11523-018-0558-1DOI Listing
June 2018

Through the Glass Ceiling.

J Clin Oncol 2018 03 25;36(9):923. Epub 2018 Jan 25.

Hervé Tilly, Centre Henri Becquerel, Université de Rouen, Institut National de la Santé et de la Recherche Médicale 1245, Rouen, France; Gilles Salles, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Université Claude Bernard Lyon-1, Institut National de la Santé et de la Recherche Médicale 1052, Pierre-Bénite, France; Thierry J. Molina, Assistance Publique-Hôpitaux de Paris, Necker, Université Paris Descartes, Paris, France; René-Olivier Casasnovas, Hôpital Le Bocage, Dijon, France; Franck Morschhauser, Université de Lille, Centre Hospitalier Universitaire Lille and Groupe de Recherche sur les Formes Injectables et les Technologies Associées, Lille, France; and Bertrand Coiffier, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Université Claude Bernard Lyon-1, Institut National de la Santé et de la Recherche Médicale 1052, Pierre-Bénite, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.76.3961DOI Listing
March 2018

Outcomes for HIV-associated diffuse large B-cell lymphoma in the modern combined antiretroviral therapy era.

AIDS 2017 11;31(18):2493-2501

aUnit of Hematology-Oncology, Centre Hospitalier de Versailles, Le ChesnaybUniversité Versailles Saint Quentin en Yvelines, Université Paris-Saclay, Communauté Paris-Saclay, PariscINSERM U1018, Centre pour la Recherche en Epidémiologie et Santé des Populations (CESP), Equipe 'Générations et Santé' Gustave Roussy, VillejuifdSorbonne Universités, INSERM, UPMC Univ Paris 06, Institut Pierre Louis d'épidémiologie et de Santé Publique (IPLESP UMRS1136), PariseUniversité Paris Sud, Faculté de médecine Paris Sud, Le Kremlin-BicêtrefPathology Unit, AP-HP, Hôpitaux Paris Sud Site Béclère, ClamartgInfectious Diseases Unit, CHU Toulouse, ToulousehInternal Medicine and Infectious Diseases Unit, CHU Bordeaux, INSERM U1219, Université de Bordeaux, BordeauxiInfectious Diseases Unit, AP-HP CHU Saint-Antoine, ParisjHIV Infection Unit, Hôpitaux Universitaires, StrasbourgkU1037, CRCT, University Toulouse III Paul SabatierlDepartment of Hematology, Institut Universitaire du Cancer (IUC), ToulousemDepartment of Hematology, AP-HP, CHU Pitié-Salpétrière, ParisnInternal Medicine Unit, AP-HP, Hôpitaux Paris Sud, Le Kremlin-BicêtreoClinical Immunology Unit, AP-HP, Hôpitaux Paris Sud Site Béclère, ClamartpDepartment of Hematology, AP-HP CHU Saint-Antoine, ParisqDepartment of Hematology, AP-HM, Assistance Publique Hôpitaux de Marseille, MarseillerImmunology Unit, AP-HP, Hôpitaux Paris Sud, Le Kremlin-BicêtresDepartment of Hematology, AP-HP, Hôpital Necker Enfants Malades, ParistHematology Unit, Centre Hospitalier Universitaire-Dijon, DijonuDepartment of Onco-Hematology, Archet Hospital, Nice, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/QAD.0000000000001652DOI Listing
November 2017

Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone.

J Clin Oncol 2017 Aug 20;35(22):2473-2481. Epub 2017 Apr 20.

Catherine Thieblemont, Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Louis; Diderot University, Sorbonne Paris-Cité; Catherine Thieblemont and Josette Briere, Descartes University; Josette Briere, Hôpital Necker, Paris; Hervé Tilly, University of Rouen, Institut National de la Santé et de la Recherche Médicale U1245, Rouen; Rene-Olivier Casasnovas, Centre Hospitalier Universitaire Dijon; Institut National de la Santé et de la Recherche Médicale UMR1231, Dijon; Christophe Fruchart, Institut d'Hématologie de Basse Normandie, Centre Hospitalier Universitaire, Caen; Franck Morschhauser, Centre Hospitalier Universitaire Régional de Lille, Lille; Corinne Haioun and Philippe Gaulard, Assistance Publique-Hôpitaux de Paris, Groupe Hospitalier Mondor; Philippe Gaulard, Institut National de la Santé et de la Recherche Médicale U955; Université Paris-Est, Créteil; Julien Lazarovici, Gustave Roussy Cancer Center, Villejuif; Aurore Perrot, University Hospital, Vandoeuvre les Nancy; Catherine Sebban, Centre Leon Berard, University Claude Bernard Lyon 1; Gilles Salles, Hospices Civils de Lyon, Université Claude Bernard U1052, Lyon; Hugo Gonzalez, Centre Hospitalier René Dubos, Pontoise; Reda Bouabdallah, Institut Paoli Calmettes, Marseille; Lucie Oberic, Institut Universitaire du Cancer-Oncopole de Toulouse, Toulouse; Bernadette Corront, Centre Hospitalier Régional Annecy, Annecy; Bachra Choufi, Centre Hospitalier Dr Duchenne, Boulogne-sur-mer; Gilles Salles and Bertrand Coiffier, Institut National de la Santé et de la Recherche Médicale U1052, Hospices Civils de Lyon, Pierre-Benite, France; Maria Gomes da Silva and Jose Cabeçadas, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisboa, Portugal; Anida Grosicka, Medical University of Silesia, Katowice, Poland; Judith Trotman, Concord Repatriation General Hospital, University of Sydney, Concord; John Catalano, Frankston Hospital and Monash University, Frankston, Australia; Dolores Caballero, Hospital Universitario de Salamanca, Salamanca; Armando Lopez-Guillermo, Hospital Clinic Barcelona, Barcelona, Spain; Richard Greil, Paracelsus Medical University Salzburg, Salzburg Cancer Research Institute; Arbeitsgemeinschaft Medikamentöse Tumortherapie, Salzburg, Austria; Koen van Eygen, Algemeen Ziekenhuis Groeninge Hospital, President Kennedylaan 4, Kortrijk; Achiel Van Hoof, Algemeen Ziekenhuis Sint Jan AV, Brugge; Andre Bosly, UCL Mont Godinne, Yvoir, Belgium; and Amos M. Cohen, Rabin Medical Center, Beilinson Hospital, Davidoff Cancer Center, Tel-Aviv University, Ramat-Aviv, Israel.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.72.6984DOI Listing
August 2017

Interim PET-driven strategy in de novo diffuse large B-cell lymphoma: do we trust the driver?

Blood 2017 06 17;129(23):3059-3070. Epub 2017 Apr 17.

Department of Hematology, CHU de Dijon, University Hospital of Dijon, Dijon, France; and.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2016-05-672196DOI Listing
June 2017

Reply to M. Lambertini et al.

J Clin Oncol 2017 03 28;35(7):805-806. Epub 2016 Nov 28.

Isabelle Demeestere, Research Laboratory on Human Reproduction, Université Libre de Bruxelles, Brussels, Belgium; Pauline Brice, St Louis Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France; Fedro A. Peccatori, European Institute of Oncology, Milan, Italy; Alain Kentos, Jolimont Hospital, Haine-Saint-Paul, Belgium; Jehan Dupuis, Henri Mondor Hospital, Paris, France; Pierre Zachee, Algemeen Ziekenhuis Stuivenberg, Antwerp, Belgium; Rene-Olivier Casasnovas, Centre Hospitalier Universitaire Dijon, Dijon, France; Eric Van Den Neste, Cliniques Universitaires Université Catholique de Louvain Saint-Luc, Brussels, Belgium; Julie Dechene, Research Laboratory on Human Reproduction, Université Libre de Bruxelles, Brussels, Belgium; Viviane De Maertelaer, Institut de Recherche Interdisciplinaire en Biologie Humaine et Moléculaire, Université Libre de Bruxelles, Belgium; Dominique Bron, J. Bordet Institute, Brussels, Belgium; and Yvon Englert, Research Laboratory on Human Reproduction, Université Libre de Bruxelles, and Erasme Hospital, Brussels, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.70.6093DOI Listing
March 2017

Reply to H.J.A. Adams et al and E. Laffon et al.

J Clin Oncol 2017 03 28;35(8):920-923. Epub 2016 Dec 28.

Michel Meignan and Anne Ségolène Cottereau, Hôpital Henri Mondor, University Paris-Est Créteil, Créteil, France; Annibale Versari, Santa Maria Nuova Hospital, Istituto di Ricovero e Cura a Carattere Scientifico, Reggio Emilia, Italy; Loïc Chartier, Centre Hospitalier Lyon Sud, Pierre Bénite, France; Jehan Dupuis, Hôpital Henri Mondor, University Paris-Est Créteil, Créteil, France; Sami Boussetta, Centre Hospitalier Lyon Sud, Pierre Bénite, France; Ilaria Grassi, Santa Maria Nuova Hospital, Istituto di Ricovero e Cura a Carattere Scientifico, Reggio Emilia, Italy; René-Olivier Casasnovas, Hôpital le Bocage, Centre Hospitalier Universitaire-Dijon, Dijon, France; Corinne Haioun, Hôpital Henri Mondor, University Paris-Est Créteil, Créteil, France; Hervé Tilly, Université de Rouen, Rouen; Vittoria Tarantino, University of Modena and Reggio Emilia, Modena, Italy; Julien Dubreuil, Centre Hospitalier Lyon Sud, Pierre Bénite, France; Massimo Federico, University of Modena and Reggio Emilia, Modena, Italy; Gilles Salles, Université Claude Bernard Lyon 1, Pierre Bénite, France; Stefano Luminari, University of Modena and Reggio Emilia, Reggio Emilia, Italy; and Judith Trotman, Concord Hospital, University of Sydney, Concord, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2016.71.0459
Publisher Site
http://dx.doi.org/10.1200/JCO.2016.71.0459DOI Listing
March 2017

[New therapy outlooks in Hodgkin lymphoma].

Bull Cancer 2017 Feb 12;104(2):182-194. Epub 2017 Jan 12.

CHU le Bocage, hématologie clinique, 14, rue Paul-Gaffarel, 21000 Dijon, France; Inserm UMR866, faculté de médecine, 7, boulevard Jeanne-d'Arc, BP 27877, 21078 Dijon cedex, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bulcan.2016.11.005DOI Listing
February 2017

Baseline Metabolic Tumor Volume Predicts Outcome in High-Tumor-Burden Follicular Lymphoma: A Pooled Analysis of Three Multicenter Studies.

J Clin Oncol 2016 Oct 30;34(30):3618-3626. Epub 2016 Sep 30.

Michel Meignan, Anne Ségolène Cottereau, Jehan Dupuis, and Corinne Haioun, Université Paris-Est Créteil, Créteil; Loïc Chartier, Sami Boussetta, and Julien Dubreuil, Centre Hospitalier Lyon Sud; Gilles Salles, Université Claude Bernard Lyon 1, Pierre Bénite; René-Olivier Casasnovas, Centre Hospitalier Universitaire-Dijon, Dijon; Hervé Tilly, Université de Rouen, Rouen, France; Annibale Versari and Ilaria Grassi, Santa Maria Nuova Hospital, Istituto Di Ricovero e Cura a Carattere Scientifico; Stefano Luminari, Arcispedale S. Maria Nuova IRCCS, University of Modena and Reggio Emilia, Reggio Emilia; Vittoria Tarantino and Massimo Federico, University of Modena and Reggio Emilia, Modena, Italy; and Judith Trotman, University of Sydney, Concord, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.66.9440DOI Listing
October 2016

The heterogeneity of changes in incidence and survival among lymphoid malignancies in a 30-year French population-based registry.

Leuk Lymphoma 2015 Apr 20;56(4):1050-7. Epub 2014 Nov 20.

Registre des Hémopathies Malignes de Côte d'Or, EA 4184, Faculté de Médecine, Université de Bourgogne , Dijon , France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/10428194.2014.956315DOI Listing
April 2015

Trends in excess mortality in follicular lymphoma at a population level.

Eur J Haematol 2015 Feb 2;94(2):120-9. Epub 2014 Aug 2.

Registre des Hémopathies Malignes de Côte d'Or, EA 4184, Université de Bourgogne, Dijon, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ejh.12403DOI Listing
February 2015

Pretherapy metabolic tumour volume is an independent predictor of outcome in patients with diffuse large B-cell lymphoma.

Eur J Nucl Med Mol Imaging 2014 Nov 6;41(11):2017-22. Epub 2014 Jun 6.

Nuclear Medicine and Lymphoid Malignancies Unit, Henri Mondor Hospital, Paris-Est University, 51 Ave. du Mal de Lattre, 94010, Créteil, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00259-014-2822-7DOI Listing
November 2014

Metabolic tumour volumes measured at staging in lymphoma: methodological evaluation on phantom experiments and patients.

Eur J Nucl Med Mol Imaging 2014 Jun 26;41(6):1113-22. Epub 2014 Feb 26.

Department of Nuclear Medicine, Hôpital Henri Mondor and Paris-Est University, Créteil, France,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00259-014-2705-yDOI Listing
June 2014

Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: Clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial.

J Clin Oncol 2014 Apr 17;32(12):1188-94. Epub 2014 Mar 17.

John M.M. Raemaekers and Richard van der Maazen, Radboud University Medical Center, Nijmegen; Pieternella J. Lugtenburg, Erasmus University Medical Center, Rotterdam; Gustaaf van Imhoff, University Medical Centre Groningen, Groningen, the Netherlands; Marc P.E. André and Thierry van der Borght, Centre Hospitalier Universitaire (CHU) L'Université Catholique de Louvain Mont Godinne, Yvoir; Yolande Lievens, Ghent University Hospital, Ghent; Tiana Raveloarivahy and Catherine Fortpied, European Organisation for Research and Treatment of Cancer, Brussels, Belgium; Massimo Federico and Monica Bellei, University of Modena and Reggio Emilia, Modena; Ercole Brusamolino, Istituto Clinico Humanitas, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Milan; Manuel Gotti, Fondazione IRCCS Policlinico San Matteo, Pavia; Allessandro Re, Spedali Civili Hospital, Brescia; Elisabetta Abruzzese, San Eugenio Hospital, Tor Vergata University, Rome; Annibale Versari, Arcispedale Santa Maria Nuova, IRCCS di Reggio Emilia, Reggio Emilia, Italy; Theodore Girinsky and Christophe Fermé, Institut Gustave Roussy, Villejuif; Reman Oumedaly, CHU Caen; Stephane Bardet, Centre Francois Baclesse, Caen; Pauline Brice, Hôpital Saint-Louis, Paris; Reda Bouabdallah, Institut Paoli Calmette, Marseille; Catherine J. Sebban, Centre Léon Bérard, Lyon; Aspasia Stamatoullas, Centre Henri Becquerel, Rouen; Frank Morschhauser, CHU de Lille, Lille; Pierre Olivier, CHU Nancy, Nancy; Rene-Olivier Casasnovas, CHU de Dijon, Dijon; Michel Meignan, Hôpital Henri Mondor, Creteil, France; and Martin Hutchings, Rigshospitalet, Kopenhagen, Denmark.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.51.9298DOI Listing
April 2014